Radiopharmaceuticals for Renal Positron Emission Tomography Imaging

Seminars in Nuclear Medicine

Volumn 38, Issue 1, 2008, Pages 20-31

  Szabo, Zsolt ^a   Xia, Jinsong ^a   Mathews, William B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID ALBUMIN GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID VASCULAR ENDOTHELIAL GROWTH FACTOR 121 CU 64; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID F 18; ACETIC ACID C 11; ALIZARIN RED S GA 68; ANGIOTENSIN RECEPTOR; ATRASENTAN; ATRASENTAN C 11; BEVACIZUMAB; CAPTOPRIL; CARBON MONO O 15; CYCLOSPORIN A; DIAGNOSTIC AGENT; ENDOTHELIN RECEPTOR; ERLOTINIB; FLUOROACETIC ACID F 18; FLUOROCAPTOPRIL F 18; INTEGRIN; N [[4' [(2 ETHYL 5,7 DIMETHYL 3H IMIDAZO[4,5 B]PYRIDIN 3 YL)METHYL] 2 BIPHENYLYL]SULFONYL]BENZAMIDE; N [[4' [(2 ETHYL 5,7 DIMETHYL 3H IMIDAZO[4,5 B]PYRIDIN 3 YL)METHYL] 2 BIPHENYLYL]SULFONYL]BENZAMIDE C 11; OXYGEN 15; PEPTIDE DERIVATIVE; PHOSPHATIDYLSERINE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RUBIDIUM 82; STRONTIUM 82; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; ZIRCONIUM 89; ZOFENOPRIL; ZOFENOPRILAT F 18;

AMYLOIDOSIS; ANGIOGENESIS; APOPTOSIS; BINDING AFFINITY; DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; GLOMERULUS; HUMAN; KIDNEY; KIDNEY BLOOD FLOW; KIDNEY CARCINOMA; KIDNEY INJURY; KIDNEY TUBULE; NEPHROTOXICITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN TARGETING; RENOVASCULAR DISEASE; REVIEW; TISSUE REPAIR;

HUMANS; IMAGE ENHANCEMENT; KIDNEY; KIDNEY DISEASES; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPE RENOGRAPHY; RADIOPHARMACEUTICALS;

EID: 37149027286     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2007.09.008     Document Type: Review

References (101)

1. Toronyi E., Hamar J., Magyar K., et al. Antiapoptotic effect of (-)-deprenyl in rat kidney after ischemia-reperfusion. Med Sci Monit 8 (2002) BR65-BR68
2. Haller H., Maasch C., Dragun D., et al. Antisense oligodesoxynucleotide strategies in renal and cardiovascular disease. Kidney Int 53 (1998) 1550-1558
3. Logan J., Fowler J.S., Volkow N.D., et al. Reproducibility of repeated measures of deuterium substituted [11C]L-deprenyl ([11C]L-deprenyl-D2) binding in the human brain. Nucl Med Biol 27 (2000) 43-49
4. Feinendegen L.E., Herzog H., Wieler H., et al. Glucose transport and utilization in the human brain: Model using carbon-11 methylglucose and positron emission tomography. J Nucl Med 27 (1986) 1867-1877
5. Tian X., Chakrabarti A., Amirkhanov N., et al. Receptor-mediated internalization of chelator-PNA-peptide hybridization probes for radioimaging or magnetic resonance imaging of oncogene mRNAs in tumours. Biochem Soc Trans 35 (2007) 72-76
6. Tian X., Chakrabarti A., Amirkhanov N.V., et al. External imaging of CCND1, MYC, and KRAS oncogene mRNAs with tumor-targeted radionuclide-PNA-peptide chimeras. Ann N Y Acad Sci 1059 (2005) 106-144
7. Redaelli C.A., Tien Y.H., Kubulus D., et al. Hyperthermia preconditioning induces renal heat shock protein expression, improves cold ischemia tolerance, kidney graft function and survival in rats. Nephron 90 (2002) 489-497
8. Eckardt K.U., Bernhardt W.M., Weidemann A., et al. Role of hypoxia in the pathogenesis of renal disease. Kidney Int Suppl (2005) S46-S51
9. Blantz R.C., Thomson S.C., Peterson O.W., et al. Physiologic adaptations of the tubuloglomerular feedback system [review]. Kidney Int 38 (1990) 577-583
10. Schnermann J., and Briggs J.P. Effect of angiotensin and other pressor agents on tubuloglomerular feedback responses. Kidney Int Suppl 30 (1990) S77-S80
11. Cervenka L., Kramer H.J., Maly J., et al. Role of nNOS in regulation of renal function in angiotensin II-induced hypertension. Hypertension 38 (2001) 280-285
12. Braam B., Navar L.G., and Mitchell K.D. Modulation of tubuloglomerular feedback by angiotensin II type 1 receptors during the development of Goldblatt hypertension. Hypertension 25 (1995) 1232-1237
13. Anderson W.P., Kett M.M., Stevenson K.M., et al. Renovascular hypertension: Structural changes in the renal vasculature. Hypertension 36 (2000) 648-652
14. Denton K.M., Anderson W.P., and Sinniah R. Effects of angiotensin II on regional afferent and efferent arteriole dimensions and the glomerular pole. Am J Physiol Regul Integr Comp Physiol 279 (2000) R629-R638
15. Denton K.M., Fennessy P.A., Alcorn D., et al. Morphometric analysis of the actions of angiotensin II on renal arterioles and glomeruli. Am J Physiol 262 (1992) F367-F372
16. Simon M., Rockl W., Hornig C., et al. Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: Localization and [125I]VEGF binding sites. J Am Soc Nephrol 9 (1998) 1032-1044
17. Kanellis J., Paizis K., Cox A.J., et al. Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expression. Kidney Int 61 (2002) 1696-1706
18. Rini B.I., and Rathmell W.K. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Clin Cancer Res 13 (2007) 741s-746s
19. Hainsworth J.D., Sosman J.A., Spigel D.R., et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23 (2005) 7889-7896
20. Nagengast W.B., de Vries E.G., Hospers G.A., et al. In Vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 48 (2007) 1313-1319
21. Cooper M.E., Vranes D., Youssef S., et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48 (1999) 2229-2239
22. Cai W., Chen K., Mohamedali K.A., et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med 47 (2006) 2048-2056
23. Aiello L.P., Pierce E.A., Foley E.D., et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92 (1995) 10457-10461
24. Robinson G.S., Pierce E.A., Rook S.L., et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 93 (1996) 4851-4856
25. Ostendorf T., De Vriese A.S., and Floege J. Renal side effects of anti-VEGF therapy in man: A new test system. Nephrol Dial Transplant 22 (2007) 2778-2780
26. Otani A., Takagi H., Suzuma K., et al. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 82 (1998) 619-628
27. Moravski C.J., Kelly D.J., Cooper M.E., et al. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 36 (2000) 1099-1104
28. Collingridge D.R., Carroll V.A., Glaser M., et al. The development of [(124)I]iodinated-VG76e: A novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 62 (2002) 5912-5919
29. Cai W., and Chen X. Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. Front Biosci 12 (2007) 4267-4279
30. Choe Y.S., and Lee K.H. Targeted in vivo imaging of angiogenesis: present status and perspectives. Curr Pharm Des 13 (2007) 17-31
31. Haubner R., Wester H.J., Weber W.A., et al. Noninvasive imaging of alpha(v) beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61 (2001) 1781-1785
32. Haubner R., Weber W.A., Beer A.J., et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2 (2005) e70
33. Chen X., Sievers E., Hou Y., et al. Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia 7 (2005) 271-279
34. Yang D.J., Kim K.D., Schechter N.R., et al. Assessment of antiangiogenic effect using 99mTc-EC-endostatin. Cancer Biother Radiopharm 17 (2002) 233-245
35. Lee K.H., Song S.H., Paik J.Y., et al. Specific endothelial binding and tumor uptake of radiolabeled angiostatin. Eur J Nucl Med Mol Imaging 30 (2003) 1032-1037
36. 18F]Fluoropropylsqualamine as an angiogenesis imaging agent. J Labelled Compounds Radiopharmaceuticals 44 (2001) S391-S392
37. Mene P., and Amore A. Apoptosis: potential role in renal diseases. Nephrol Dial Transplant 13 (1998) 1936-1943
38. Gobe G.C., Harmon B., Leighton J., et al. Radiation-induced apoptosis and gene expression in neonatal kidney and testis with and without protein synthesis inhibition. Int J Radiat Biol 75 (1999) 973-983
39. Murakami Y., Takamatsu H., Taki J., et al. 18F-labelled annexin V: A PET tracer for apoptosis imaging. Eur J Nucl Med Mol Imaging 31 (2004) 469-474
40. Keen H.G., Dekker B.A., Disley L., et al. Imaging apoptosis in vivo using 124I-annexin V and PET. Nucl Med Biol 32 (2005) 395-402
41. Bauer C., Bauder-Wuest U., Mier W., et al. 131I-Labeled peptides as caspase substrates for apoptosis imaging. J Nucl Med 46 (2005) 1066-1074
42. Cauchon N., Langlois R., Rousseau J.A., et al. PET imaging of apoptosis with (64)Cu-labeled streptavidin following pretargeting of phosphatidylserine with biotinylated annexin-V. Eur J Nucl Med Mol Imaging 34 (2007) 247-258
43. Aloya R., Shirvan A., Grimberg H., et al. Molecular imaging of cell death in vivo by a novel small molecule probe. Apoptosis 11 (2006) 2089-2101
44. Dember L.M. Amyloidosis-associated kidney disease. J Am Soc Nephrol 17 (2006) 3458-3471
45. Sasatomi Y., Sato H., Chiba Y., et al. Prognostic factors for renal amyloidosis: A clinicopathological study using cluster analysis. Intern Med 46 (2007) 213-219
46. Hawkins P.N. Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo. Clin Sci 87 (1994) 289-295 (Lond)
47. Schaffer J., Burchert W., Floege J., et al. Recombinant versus natural human 111In-beta2-microglobulin for scintigraphic detection of Abeta2m amyloid in dialysis patients. Kidney Int 58 (2000) 873-880
48. Schaadt B.K., Hendel H.W., Gimsing P., et al. 99mTc-aprotinin scintigraphy in amyloidosis. J Nucl Med 44 (2003) 177-183
49. Wall J.S., Kennel S.J., Paulus M., et al. Radioimaging of light chain amyloid with a fibril-reactive monoclonal antibody. J Nucl Med 47 (2006) 2016-2024
50. Goethals P., Volkaert A., Vandewielle C., et al. 55Co-EDTA for renal imaging using positron emission tomography (PET): A feasibility study. Nucl Med Biol 27 (2000) 77-81
51. Yamashita M., Inaba T., Kawase Y., et al. Quantitative measurement of renal function using Ga-68-EDTA. Tohoku J Exp Med 155 (1988) 207-208
52. Greene M.W., and Tucker W.D. An improved gallium-68 cow. Int J Appl Radiat Isot 12 (1961) 62-63
53. Ehrhardt G.J., and Welch M.J. A new germanium-63/gallium-68 generator. J Nucl Med 19 (1978) 925-929
54. Schuhmacher J., Maier-Borst W., and Wellman H.N. Liver and kidney imaging with Ga-68-labeled dihydroxyanthraquinones. J Nucl Med 21 (1980) 983-987
55. Young H., Carnochan P., Zweit J., et al. Evaluation of copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) for tissue blood flow measurement using a trapped tracer model. Eur J Nucl Med 21 (1994) 336-341
56. Shelton M.E., Green M.A., Mathias C.J., et al. Assessment of regional myocardial and renal blood flow with copper-PTSM and positron emission tomography. Circulation 82 (1990) 990-997
57. Nitzsche E.U., Choi Y., Killion D., et al. Quantification and parametric imaging of renal cortical blood flow in vivo based on Patlak graphical analysis. Kidney Int 44 (1993) 985-996
58. Killion D., Nitzsche E., Choi Y., et al. Positron emission tomography: A new method for determination of renal function. J Urology 150 (1993) 1064-1068
59. Brooks D.J., Frackowiak R.S., Lammertsma A.A., et al. A comparison between regional cerebral blood flow measurements obtained in human subjects using 11C-methylalbumin microspheres, the C15O2 steady-state method, and positron emission tomography. Acta Neurol Scand 73 (1986) 415-422
60. Turton D.R., Brady F., Pike V.W., et al. Preparation of human serum [methyl-11C]methylalbumin microspheres and human serum [methyl-11C]methylalbumin for clinical use. Int J Appl Radiation and Isotopes 35 (1984) 337-344
61. Mintun M.A., Ter Pogossian M.M., Green M.A., et al. Quantitative measurement of regional pulmonary blood flow with positron emission tomography. J Appl Physiol 60 (1986) 317-326
62. Hermansen F., Ashburner J., Spinks T.J., et al. Generation of myocardial factor images directly from the dynamic oxygen-15-water scan without use of an oxygen-15-carbon monoxide blood-pool scan. J Nucl Med 39 (1998) 1696-1702
63. Kubo T., Kimori K., Nakamura F., et al. Blood flow and blood volume in the femoral heads of healthy adults according to age: measurement with positron emission tomography (PET). Ann Nucl Med 15 (2001) 231-235
64. Kihlberg T., Karimi F., and Langstrom B. [(11)C] Carbon monoxide in selenium-mediated synthesis of (11)C-carbamoyl compounds. J Org Chem 67 (2002) 3687-3692
65. Hofman H.A., Knaapen P., Boellaard R., et al. Measurement of left ventricular volumes and function with O-15-labeled carbon monoxide gated positron emission tomography: comparison with magnetic resonance imaging. J Nucl Cardiol 12 (2005) 639-644
66. Okazawa H., Yonekura Y., Fujibayashi Y., et al. Measurement of regional cerebral plasma pool and hematocrit with copper-62-labeled HSA-DTS. J Nucl Med 37 (1996) 1080-1085
67. Hoffend J., Mier W., Schuhmacher J., et al. Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo. Nucl Med Biol 32 (2005) 287-292
68. Shreve P., Chiao P.C., Humes H.D., et al. Carbon-11-acetate PET imaging in renal disease. J Nucl Med 36 (1995) 1595-1601
69. Ponde D.E., Dence C.S., Oyama N., et al. 18F-fluoroacetate: A potential acetate analog for prostate tumor imaging-in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med 48 (2007) 420-428
70. Johnson H.A. Diagnosis by the bit: A method for evaluating the diagnostic process. Ann Clin Lab Sci 19 (1989) 323-331
71. Szabo Z., Speth R.C., Brown P.R., et al. Use of positron emission tomography to study AT1 receptor regulation in vivo. J Am Soc Nephrol 12 (2001) 1350-1358
72. Owonikoko T.K., Fabucci M.E., Brown P.R., et al. In vivo investigation of estrogen regulation of adrenal and renal angiotensin AT1 receptor expression by PET. J Nucl Med 45 (2003) 94-100
73. Weinberger M.H., Fineberg N.S., Fineberg S.E., et al. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension 37 (2001) 429-432
74. Szabo Z., Mathews W.B., Burns H.D., Gibson R.E., Kivlighn S.D., Hamill T.G., Ravert H.T., and Dannals R.F. Comparison of the pharmacological potency and AT1 receptor occupancy of the nonpeptide angiotensin antagonist E-3174. J Nucl Med 37 (1996) 288P
75. Kao P.F., Szabo Z., Dannals R.F., et al. Compartmental modeling of an angiotensin IP/AT1 receptor imaging agent: C-11 L-159,884. J Nucl Med 35 (1994) 137P
76. Kao P.F., Szabo Z., Dannals R.F., et al. Impulse response function of the angiotensin II/AT1 receptor imaging agent: Carbon-11 L-159,884. Eur J Nucl Med 21 suppl (1994) 774
77. Kim S.E., Scheffel U., Szabo Z., et al. In vivo labeling of angiotensin II receptors with a carbon-11-labeled selective nonpeptide antagonist. J Nucl Med 37 (1996) 307-311
78. Szabo Z., Sandberg K., Brown P., et al. Increased AT1 receptor expression after treatment with the ACE inhibitor lisinopril. J Nucl Med 40 (1999) 92P-93P
79. Szabo Z., Kao P.F., Burns H.D., et al. Investigation of angiotensin II/AT1 receptors with carbon-11-L-159,884: a selective AT1 antagonist. J Nucl Med 39 (1998) 1209-1213
80. Zober T.G., Brown R.P., Sandberg K., et al. PET demonstrates upregulation of the renal angiotensin-II (AT1) receptors in experimental renovascular hypertension. J Nucl Med 44 (2003) 142P
81. Szabo Z., Kao P.F., Mathews W.B., et al. Validation of the impulse response function of [C-11]L-159,884, an angiotensin II, AT1 selective tracer. J Nucl Med 37 (1996) 288P
82. Hong K.W., Kim C.D., Lee S.H., et al. The in vitro pharmacological profile of KR31080, a nonpeptide AT1 receptor antagonist. Fundam Clin Pharmacol 12 (1998) 64-69
83. Lee B.H., Seo H.W., Kwon K.J., et al. In vivo pharmacologic profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist. J Cardiovasc Pharmacol 33 (1999) 375-382
84. Mathews W.B., Yoo S.E., Lee S.H., et al. A novel radioligand for imaging the AT1 angiotensin receptor with PET. Nucl Med Biol 31 (2004) 571-574
85. 11C]KR31173 and PET in mice, dogs and baboons. Nucl Med Biol 33 (2006) 5-13
86. Kim S., and Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52 (2000) 11-34
87. Unger T., and Gohlke P. Converting enzyme inhibitors in cardiovascular therapy: current status and future potential. Cardiovasc Res 28 (1994) 146-158
88. Hwang D.R., Eckelman W.C., Mathias C.J., et al. Positron-labeled angiotensin-converting enzyme (ACE) inhibitor: fluorine-18-fluorocaptopril. Probing the ACE activity in vivo by positron emission tomography. J Nucl Med 32 (1991) 1730-1737
89. Qing F., McCarthy T.J., Markham J., et al. Pulmonary angiotensin-converting enzyme (ACE) binding and inhibition in humans. A positron emission tomography study. Am J Respir Crit Care Med 161 (2000) 2019-2025
90. Matarrese M., Salimbeni A., Turolla E.A., et al. 11C-Radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]zofenoprilat. Bioorg Med Chem 12 (2004) 603-611
91. Naicker S., and Bhoola K.D. Endothelins: Vasoactive modulators of renal function in health and disease. Pharmacol Ther 90 (2001) 61-88
92. Khan M.A., Dashwood M.R., Mumtaz F.H., et al. Upregulation of endothelin A receptor sites in the rabbit diabetic kidney: potential relevance to the early pathogenesis of diabetic nephropathy. Nephron 83 (1999) 261-267
93. Gibson R.E., Fioravanti C., Francis B., et al. Radioiodinated endothelin-1: A radiotracer for imaging endothelin receptor distribution and occupancy. Nucl Med Biol 26 (1999) 193-199
94. Johnstrom P., Harris N.G., Fryer T.D., et al. (18)F-Endothelin-1, a positron emission tomography (PET) radioligand for the endothelin receptor system: Radiosynthesis and in vivo imaging using microPET. Clin Sci 103 Suppl 48 (2002) 4S-8S (Lond)
95. Ravert H.T., Mathews W.B., Hamill T.G., et al. Radiosynthesis of a potent endothelin receptor antagonist. J Label Compounds Radiopharm 43 (2000) 1205-1210
96. 11C]L-753,037: Studies in mice and a dog. J Nucl Med 42 (2001) 1274-1280
97. Johnstrom P., Aigbirhio F.I., Clark J.C., et al. Syntheses of the first endothelin-A- and -B-selective radioligands for positron emission tomography. J Cardiovasc Pharmacol 36 (2000) S58-S60
98. Johnstrom P., Rudd J.H., Richards H.K., et al. Imaging endothelin ET(B) receptors using [18F]-BQ3020: In vitro characterization and positron emission tomography (microPET). Exp Biol Med (Maywood) 231 (2006) 736-740
99. Hoeltke C., Wagner S., Breyholz H.J., et al. Development, synthesis and in vitro evaluation of novel ET-A receptor PET-radioligands based on PD 156707. J Label Compds Radiopharm 50 (2007) S345
100. Johnstrom P., Fryer T.D., Richards H.K., et al. In vivo imaging of cardiovascular endothelin receptors using the novel radiolabelled antagonist [18F]-SB209670 and positron emission tomography (microPET). J Cardiovasc Pharmacol 44 (2004) S34-S38
101. Mathews W.B., Zober T.G., Ravert H.T., et al. Synthesis and in vivo evaluation of a PET radioligand for imaging the endothelin-A receptor. Nucl Med Biol 33 (2006) 15-19